Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Who May Qualify: • Postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia Who Should NOT Join This Trial: - a bone disease other than postmenopausal osteoporosis - use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study - creatinine clearance \<60 mL/min/1.73 m2 - liver failure - any type of cancer - uncontrolled endocrine diseases - serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L) Always talk to your doctor about whether this trial is right for you.